VIGNA, ERNESTO
 Distribuzione geografica
Continente #
NA - Nord America 348
EU - Europa 245
AS - Asia 151
AF - Africa 2
Totale 746
Nazione #
US - Stati Uniti d'America 346
IT - Italia 179
CN - Cina 108
SG - Singapore 35
FI - Finlandia 20
DE - Germania 14
AT - Austria 10
NL - Olanda 7
UA - Ucraina 5
CZ - Repubblica Ceca 2
ET - Etiopia 2
GB - Regno Unito 2
JP - Giappone 2
KR - Corea 2
PA - Panama 2
DK - Danimarca 1
ES - Italia 1
FR - Francia 1
HK - Hong Kong 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
SE - Svezia 1
Totale 746
Città #
Boardman 130
Florence 110
Ashburn 42
Shanghai 41
Sesto Fiorentino 22
Singapore 21
Noto 20
Helsinki 13
Washington 12
Vienna 10
Guangzhou 9
Los Angeles 9
Lappeenranta 7
Naaldwijk 7
Ogden 7
Wuhan 7
Beijing 6
Chandler 4
Jinhua 3
Munich 3
Palmi 3
Rome 3
Addis Ababa 2
Ann Arbor 2
Bari 2
Gualdo Tadino 2
Milan 2
Naples 2
New York 2
San Francisco 2
Seoul 2
Tokyo 2
Turin 2
West Jordan 2
Bologna 1
Brooklyn 1
Catania 1
Central 1
Chicago 1
Chizhou 1
Cirò Marina 1
Cologne 1
Des Moines 1
Frankfurt am Main 1
Hamm 1
Hangzhou 1
Jining 1
Lawrence 1
Lianyun 1
Luxembourg 1
Macao 1
Madrid 1
Manila 1
Miami 1
Modigliana 1
Mountain View 1
Ningbo 1
Qingdao 1
Rende 1
Roxbury 1
San Mateo 1
Santa Barbara 1
Santa Clara 1
Shenzhen 1
Taizhou 1
Tiantai Chengguanzhen 1
Udine 1
Vientiane 1
Yiwu 1
Zibo 1
Totale 549
Nome #
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 44
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 30
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 30
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 28
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 28
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 27
Teclistamab-cqyv in multiple myeloma 26
Elotuzumab in multiple myeloma 26
Iron chelation therapy 25
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 24
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 24
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 23
Belantamab mafodotin in multiple myeloma 23
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 22
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 22
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 22
Cerebral pheohyphomycosis due to curvularia species 21
Myelodysplastic syndromes with ring sideroblasts 21
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 21
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 21
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 20
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 19
Acalabrutinib in chronic lymphocytic leukemia 18
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 17
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 15
Ivosidenib in acute myeloid leukemia 14
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 14
Glasdegib for the treatment of acute myeloid leukemia 13
Isatuximab in multiple myeloma 13
Momelotinib in myelofibrosis 13
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 13
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 12
Selinexor in multiple myeloma 11
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 10
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 10
Zanubrutinib for the treatment of chronic lymphocytic leukemia 10
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 9
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 9
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 9
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 9
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 7
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 6
Venetoclax in acute myeloid leukemia 6
Tagraxofusp in myeloid malignancies 6
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 5
Totale 796
Categoria #
all - tutte 7.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.844


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202376 2 0 0 2 1 1 32 3 4 5 20 6
2023/2024536 10 17 105 85 49 64 24 18 17 9 19 119
2024/2025168 48 104 16 0 0 0 0 0 0 0 0 0
Totale 796